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Epidemiological and experimental studies report associations between overweight mothers and increased obesity risk in oﬀspring.
It is unclear whether neonatal leptin regulation mediates this association between overweight mothers and oﬀspring obesity. We
investigated the eﬀect of neonatal treatment with a leptin antagonist (LA) on growth and metabolism in oﬀspring of mothers fed
either a control or a high fat diet. Wistar rats were fed either a control (CON) or a high fat diet (MHF) during pregnancy and
lactation. Male CON and MHF neonates received either saline (S) or a rat-speciﬁc pegylated LA on days 3, 5, and 7. Oﬀspring were
weaned onto either a control or a high fat (hf) diet. At day 100, body composition, blood glucose, β-hydroxybutyrate and plasma
leptin and insulin were determined. In CON and MHF oﬀspring, LA increased neonatal bodyweights compared to saline-treated
oﬀspring and was more pronounced in MHF oﬀspring. In the post-weaning period, neonatal LA treatment decreased hf diet-
induced weight gain but only in CON oﬀspring. LA treatment induced changes in body length, fat mass, body temperature, and
bone composition. Neonatal LA treatment can therefore exert eﬀects on growth and metabolism in adulthood but is dependent
upon interactions between maternal and post-weaning nutrition.
1.Introduction
Obesity and metabolic-related disorders are considered
major health issues worldwide. Over the last decade, the in-
cidence of obesity and overweight has almost doubled in
developed countries and the trend is mirrored in developing
nations that are transitioning to ﬁrst-world economies [1].
Obesityresultsfromaninteractionofmanyfactorsincluding
genetic, physiologic, behavioural, and environmental inﬂu-
ences. However, the rapid increases in the rates of obesity
suggest that environmental and behavioural inﬂuences,
rather than genetic causes, are fuelling the present epidemic.
Increasingevidencefrombothclinicalandanimalstudies
has highlighted the link between altered maternal nutrition
and the risk of oﬀspring developing obesity and the meta-
bolic syndrome [2–5]. Initial epidemiological studies sug-
gested that fetal growth restriction is correlated with later
disease, implying that fetal nutritional deprivation may be a
strong stimulus for developmental programming. However,
although maternal nutrient deprivation has been well char-
acterized in this context, in many societies, maternal and
postnatal nutrition can be excessive. As a result, excessive
weightgainand/orobesityarecommonnutritionalproblems
complicating pregnancy in developed countries. As such,
there is now accumulating evidence from human [6]a n d
animal studies suggesting that excess maternal caloric intake
has adverse eﬀects on the health and well-being of oﬀspring,
independent of postnatal diet [7] and exerted transgenera-
tional eﬀects [8].
Maternal obesity has many adverse outcomes, including
labour and delivery complications, fetal and neonatal death,
maternal hypertension, and preeclampsia and gestational
diabetes [9–12]. In addition to acute risks to the obese
mother, negative outcomes extend to oﬀspring, including
obesity and cardiovascular disease in adulthood [13–16]. On
one hand, while a shared postnatal environment and genetic
susceptibility are likely contributors [17], maternal BMI is
reported in some cohorts as having greater inﬂuence on2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
oﬀspring than paternal BMI, highlighting the independent
inﬂuence of the intrauterine environment on oﬀspring
adiposity [18].
In a rodent model, we recently reported that oﬀspring
born to high-fat-fed mothers showed an obese phenotype
in adulthood characterised by hyperinsulinemia and hyper-
leptinemia, independent of postnatal diet [7, 19]. Although
the mechanistic drivers underlying this obesogenic pheno-
type are still unclear, experimental data in rodents suggest
that leptin plays a critical role in underpinning early life
inﬂuences on postnatal phenotypic development [20–22].
Early studies demonstrated that leptin, an adipokine pro-
duced primarily by adipocytes, plays a key role in regulation
of energy homeostasis and food intake via its action on
speciﬁc hypothalamic nuclei [23]. Leptin has been since
demonstrated to exert other important functions, including
itsregulationofbonegrowth,skeletalmetabolism,andlinear
growth via direct eﬀects on osteoblast and osteocalcin release
and growth hormone secretion, respectively [24, 25].
In rodents, a characteristic of the neonatal period is a
leptin surge, which normally peaks in the second week of
neonatallife[26].Ithasbeenshownthatearlylifenutritional
insults aﬀect this surge resulting in altered hypothalamic
development [27, 28]. Maternal undernutrition in rats has
been shown to result in a blunted and altered timing of the
leptin surge in neonatal pups [27], and leptin adminis-
tration during the neonatal period in ob/ob mice nor-
malisedhypothalamicdevelopmentandpartiallynormalised
orexigenic behaviour [21]. Importantly, postweaning leptin
administration had no eﬀect [27], emphasising that, in the
rat, the critical stage of hypothalamic leptin regulation is
during the ﬁrst 2 weeks of neonatal life. Our group has
previously shown that neonatal leptin treatment can reverse
the deleterious eﬀects of maternal undernutrition on post-
natal outcomes in male and female oﬀspring [29, 30]. In
contrast, Kirk et al. reported that maternal high-fat diet led
to an ampliﬁed leptin surge in neonatal pups during the ﬁrst
2 weeks of life, resulting in altered hypothalamic regulation
of food intake [31].
There is growing evidence that leptin plays a signiﬁcant
role in the development of an obesogenic phenotype after
early-life exposure to an imprudent diet. Despite this, no
studies have investigated whether maternal high-fat-diet-
induced changes in neonatal leptin action regulate this asso-
ciation. We, therefore, hypothesized that leptin blockade,
using a speciﬁc leptin antagonist, during the critical neonatal
period of leptin sensitivity would ameliorate maternal high-
fat-induced obesogenic eﬀects on oﬀspring [7]. We investi-
gated the eﬀect of leptin antagonist administration during
the time of the critical neonatal leptin surge on weight gain,
food intake, and body composition in male oﬀspring born to
mothers fed either a control or a high-fat diet.
2. Methods
2.1. Animal Model. The animal model of maternal high-fat
nutrition has been described in detail previously [7, 19].
Brieﬂy, female Wistar rats were time-mated using a rat estrus
cycle monitor (EC40, Fine Science Tools, Foster City, CA,
USA) to assess the stage of estrus of the animal before
introducing the male. Upon conﬁrmation of mating, rats
were randomly assigned to one of two maternal diets: the
control chow diet throughout pregnancy and lactation
(CON, n = 11 litters, Diet 2018, Harlan-Teklad, Oxon, UK)
or a high-fat diet (MHF, n = 13 litters, 45%kcals from fat,
D12451, Research Diets, New Brunswick, NJ, USA) to be
fed ad libitum throughout pregnancy and lactation. Females
were housed individually, with free access to water, and
bodyweight and food intakes were measured every two days
until the end of lactation. At birth, pups were weighed, and
on postnatal day 2, litter size was adjusted to 8 pups per litter
toensureadequateandstandardizednutritionuntilweaning.
At postnatal day 3, MHF and CON litters were randomly
assigned to receive either saline (S) or pegylated rat leptin
antagonist (LA, mutant L39A/D40A/F41A, Protein Labora-
toriesRehovot,Israel).TheLAorsalinewasadministratedby
subcutaneous injection at postnatal days 3, 5, and 7 at a dose
of 12.5μg/g. Dosage and timing of LA administration was
derived from calculated half-life (approximately 20 hours)
a n dp r i o rc i t e dp u b l i c a t i o n s[ 32]. Male pups were weighed
daily during the treatment period and then every 2 days
thereafter until weaning (P22). At weaning, saline- and LA-
treated CON and MHF male oﬀspring were housed two per
cage, and randomly placed on either the control rat chow (c)
or high-fat (hf) diet until the completion of the trial (day
110). A schematic of the study design is shown in Figure 1.
Body weights and caloric intakes were recorded in
oﬀspring every 3 days until the end of the study. Body com-
position (fat mass, bone mineral content (BMC), and bone
mineral density (BMD)) was measured by dual-energy X-
ray absorptiometry (DEXA) at P100 under light isoﬂurane
(2%) anaesthesia and using a dedicated small animal soft-
ware package (Lunar Hologic, Waltham, MA). Rats were
culled at P110 by decapitation following anaesthesia with
sodium pentobarbitone (60mg/kg). A tail blood sample
was taken for fasting glucose and β-hydroxybutyrate (BHB)
measurements (Roche Accucheck) and a rectal temperature
measurement recorded. Trunk blood was collected into
heparinised vacutainers, centrifuged and plasma stored at
−20◦C for later analysis. All animal work was approved by
the Animal Ethics Committee of the University of Auckland.
2.2. Plasma Analyses. Plasma leptin and insulin concentra-
tions were analysed using commercially available rat-speciﬁc
ELISAs (no. 900040 and no. 90060, resp., CrystalChem, IL,
USA).
2.3. Statistical Analysis. Data were analysed using JMP 7
(SAS Institute Inc., Cary, NC, USA) and R software (v.2.9.0,
R Foundation for Statistical Computing, Vienna, Austria)
f o rW i n d o w s .A l ld a t aa r ep r e s e n t e da sm e a n± SEM unless
otherwise stated. All models were statistically validated for
assumptions of normality of residuals and absence of
heteroscedasticity. Nonnormal data were log transformed to
normalize where necessary. Maternal pregnancy data and
neonatal data at birth were analysed using one-way ANOVA.J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
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Figure 1: Schematic showing experimental design. There are two levels of maternal nutrition, 2 levels of neonatal treatment, and 2 levels of
postweaning diet resulting in a total of 8 experimental groups in a fully balanced 2 × 2 × 2 design.
Maternal caloric intakes; weight and body composition
during lactation was analysed by two-way ANOVA with ma-
ternal diet and treatment group as factors and litter as
covariate. Neonatal and postweaning growth was analysed
byrepeatedmeasuresfactorialANOVA.Althoughthegrowth
analysiswasperformedonabsolutebodyweightdata,growth
ﬁgures are shown as relative changes for sake of clarity given
the number of experimental groups involved. Preweaning
dataforpupswasanalysedbytwo-wayfactorialANOVAwith
maternal diet and LA administration as factors, and their
interactions. Data from adult oﬀspring were analyzed by
three-way factorial ANOVA with maternal diet, postweaning
diet, and LA treatment as factors, and the interaction be-
tween these factors (litter included as a covariate). Post hoc
multiple pairwise comparisons were performed using Tukey
test. Level of signiﬁcance was set at P<0.05.
3. Results
3.1. Maternal Data. Consistent with our previous observa-
tions [7], maternal HF diet during pregnancy and lactation
resulted in a transient increase in caloric intake from day 2
(P<0.001) to day 15 of gestation when intakes returned to
levels similar to those observed in CON dams (data not
shown). Increased caloric intake in MHF dams was reﬂected
in an increased maternal weight gain by gestational day 7
(P = 0.04, Figure 2), which persisted until birth. MHF dams
remained heavier than controls from the early neonatal
period until mid-lactation when body weights returned to
match those of controls. There was no overall signiﬁcant
eﬀect of neonatal LA administration on weight or caloric
intake of dams during pregnancy and lactation. At weaning,
despite a similar maternal body weight, total fat mass (%)
andfat:leanratios(F/L)weresigniﬁcantlyincreasedinMHF
dams compared to CON (% fat: CON 14.7 ± 1.7% versus
MHF 22.9 ± 2.3, P = 0.01; F/L: CON 0.18 ± 0.08 versus
MHF 0.31 ± 0.16, P = 0.01). There was no signiﬁcant
eﬀect of neonatal LA treatment or an interaction between
treatment and maternal diet, on body composition of dams.
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Figure 2: Maternal body weights during pregnancy and lactation.
There was no overall signiﬁcant eﬀect of neonatal LA administra-
tion on weight of dams during pregnancy and lactation thus data
for Sal and LA groups for each respective maternal diet have been
combined. Data are means ± SEM with a minimum of 5 litters per
group.
3.2. Neonatal Growth. Birthweights were slightly but signiﬁ-
cantly reduced in male oﬀspring of MHF dams compared to
CON (CON 6.2 ± 0.1g; MHF 5.9 ± 0.1g, P<0.001). At P3
and prior to start of LA administration, pups born to MHF
mothers remained lighter than CON neonates (CON 7.1 ±
0.1g; MHF 6.8 ± 0.1g, P<0.05).
LA administration leads to an increased neonatal weight
gain in CON and MHF oﬀspring compared to their saline
treated counterparts (P<0.005, Figure 3). The increased
weight gain in LA-treated neonates was more pronounced in4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 3: (a) Absolute body weights in male oﬀspring from birth until weaning and (b) changes in neonatal body weights (grams, shown
as delta diﬀerence in body weight between LA and Sal treated oﬀspring, ΔLA-Sal) in CON and MHF neonates from birth until the time of
weaning (day 22). Arrows indicate time of injection with LA at neonatal days 3, 5, and 7. P<0.005 for eﬀect of LA treatment; maternal diet
× LA treatment interaction P<0.05. N = minimum 16 per group.
oﬀspring of MHF dams reﬂected in a maternal diet × LA
treatment interaction (P<0.005). By weaning (P22),
MHF oﬀspring were slightly but signiﬁcantly heavier than
CON oﬀspring and LA treatment further increased weaning
weights in CONT and MHF oﬀspring (P22: CON-S 59.9 ±
0.9g, CON-LA 62.0 ± 1.1g, MHF-S 61.8 ± 1.7g, MHF-LA
66.3 ± 1.1g, P<0.05 for eﬀect of maternal diet and LA
treatment, no interactions).
3.3. Postweaning Growth and Body Composition. An MHF
diet had no signiﬁcant eﬀect on adult body weight at post-
natal day 110 but resulted in signiﬁcantly increased total
percent body fat and decreased lean body weight percentage
compared to CON animals as quantiﬁed by DEXA scanning
(Table 1). A postweaning hf diet increased body weight
and total body fat mass in all hf-fed groups. Neonatal LA
treatment had a signiﬁcant overall eﬀect on reducing total
percent body fat mass, increasing lean mass and a decreased
fat:lean ratio (Table 1). A signiﬁcant maternal diet × LA
treatment × postnatal diet interaction (P<0.001) revealed
that body weights were signiﬁcantly reduced in oﬀspring of
CON dams that were treated as neonates with LA and fed
a postweaning hf diet as compared to saline treated CON
oﬀspring fed the hf diet (Figure 4(c)). LA treatment in CON
neonates reduced hf diet-induced obesity by approximately
10% and equated to an absolute bodyweight diﬀerence of
72.6g (Figure 4(a)). DEXA analysis of body fat content
showed that this reduction in body fat was paralleled by a
reduction in fat mass in these animals compared to saline
treated (Figure 4(d)). This eﬀe c tw a sn o to b s e r v e di nM H F
oﬀspring where neonatal LA failed to signiﬁcantly impact on
postweaning hf-induced changes in ﬁnal bodyweight or fat
mass (Figures 4(b) and 4(d) and Table 1). This may reﬂect
a more marked increase in relative lean mass in LA-treated
CON-hf oﬀspring as compared to LA treated MHF-hf oﬀ-
spring compared to relative saline-treated groups (Table 1).
There were no signiﬁcant eﬀects of MHF diet, neonatal
LA treatment, or postweaning hf diet on total caloric intake
(expressed as kcals consumed per gram body weight) across
any of the treatment groups (Figures 5(a) and 5(b)).
There were signiﬁcant overall eﬀects of maternal diet and
LA treatment on nose-anus (NA) length (Table 1). Post hoc
analysis revealed LA treatment increased NA length in MHF
oﬀspring but not CON oﬀspring as reﬂected in a maternal
diet × LA treatment interaction (P<0.05). A postweaning
hf diet increased NA length only in MHF oﬀspring (Table 1).
Maternal diet had no overall eﬀect on nose-tail (NT)
length (Table 1). There were overall signiﬁcant eﬀects of
neonatalLAtreatmentandpostweaninghfdietonincreasing
NT length. A signiﬁcant maternal diet × LA treatment
interaction revealed that increases in NT length as a result
of neonatal LA treatment were greater in MHF oﬀspring
compared to CON oﬀspring for both chow and postweaning
hf diets (Table 1).
3.4. Bone Mineral Density (BMD). There was no eﬀect
of MHF diet on BMD (Table 1). Neonatal LA treatment
reduced BMD in all treatment groups and a postweaningJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
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Figure 4: Body weights in male oﬀspring of either CON (a) or MHF (b) mothers treated with either saline or LA as neonates and fed
either a chow or hf diet after weaning. Data are means ± SEM, n = minimum 8 per group; (c) change in body weight (grams, shown as
delta diﬀerence in body weight between LA and Sal-treated oﬀspring, ΔLA-Sal) in CON and MHF oﬀspring fed either a control chow or hf
diet from weaning until postnatal day 110. Data are means ± SEM, n = minimum 8 per group. Maternal diet × LA treatment interaction
P<0.005; (d) fat mass (g) as quantiﬁed by DEXA scanning in oﬀspring of CON of MHF dams, treated with either Sal or LA as neonates and
fed either a control chow or hf diet after weaning. Data are means ± SEM, minimum of 8 per group. ∗P<0.05.
hf diet increased BMD in all oﬀspring. There were no
statistically signiﬁcant interactions.
3.5. Bone Mineral Content (BMC). An MHF diet had the
overall eﬀect of increasing BMC in all oﬀspring (Table 1).
Neonatal LA treatment reduced BMC in all treated groups
and a postweaning hf diet increased BMC in all oﬀspring.
There were no statistically signiﬁcant interactions.
3.6. Rectal Temperature (RT). An MHF diet signiﬁcantly
increased RT in all MHF oﬀspring (Table 2). Neonatal LA
treatment reduced RT in all treatment groups. A postwean-
ing hf diet had no signiﬁcant eﬀect on RT (P = 0.092). There
were no statistically signiﬁcant interactions.
3.7. Leptin, Insulin, Glucose, and β-Hydroxybutyrate (BHB)
Levels. An MHF diet signiﬁcantly increased plasma lep-
tin levels in all MHF oﬀspring (Table 2). Neonatal LA
treatment had no overall eﬀect on plasma leptin lev-
els. A postweaning hf diet increases plasma leptin in
all hf-fed oﬀspring. There were no statistically signiﬁ-
cant interactions for plasma leptin. There was a strong6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 5: Total caloric intake (kcals consumed per gram body weight) in male oﬀspring of CON mothers (a) or MHF mothers (b) from
birth until the completion of the trial. Data are average caloric intakes per cage of 2 animals, minimum of 4 cages per group.
Table 1: Adult (P110) body weight, total fat (%), body length, bone density, and mineral content in CON or MHF oﬀspring treated with
either saline (S) or pegylated leptin antagonist (LA) as neonates and fed either a chow or hf diet after weaning. Data are means ± SEM,
n = 8–16 per group.
Group Final body
weight (g)
Total body
Fat (%)
Lean mass
(%)
Fat:lean
ratio
Nose-anus
(mm) Nose-tail (mm) BMD (g/cm2)B M C ( g )
CON-S-chow 590 ± 10 31.0 ± 2.3 67.2 ± 2.2 0.47 ± 0.05 277 ± 2 478 ± 2 0.174 ± 0.001 14.8 ± 0.4
CON-S-hf 723 ± 19 46.6 ± 2.6 52.0 ± 2.5 0.91± 0.09 279 ± 2 484 ± 4 0.183 ± 0.003 17.6 ± 0.6
CON-LA-chow 595 ± 17 29.1 ± 1.1 69.3 ± 0.9 0.43 ± 0.02 277 ± 3 479 ± 4 0.171 ± 0.002 14.5 ± 0.2
CON-LA-hf 650 ± 21 37.9 ± 3.1 60.0 ± 3.8 0.72 ± 0.09 278 ± 2 489 ± 3 0.174 ± 0.003 15.8 ± 0.6
MHF-S-chow 621 ± 11 38.9 ± 2.1 59.6 ± 2.1 0.65 ± 0.06 277 ± 2 477 ± 3 0.176 ± 0.002 15.7 ± 0.3
MHF-S-hf 729 ± 18 51.0 ± 1.6 47.8 ± 1.5 1.06 ± 0.07 280 ± 2 480 ± 3 0.187 ± 0.003 18.7 ± 0.4
MHF-LA-chow 624 ± 13 34.9 ± 1.5 63.5 ± 1.5 0.54 ± 0.03 283 ± 1 490 ± 2 0.171 ± 0.001 14.8 ± 0.3
MHF-LA-hf 710 ± 18 44.1 ± 3.0 50.8 ± 1.9 0.94 ± 0.08 287 ± 2 493 ± 4 0.179 ± 0.002 17.5 ± 0.4
Main eﬀects
Maternal diet (MD) P<0.05 P<0.005 P<0.0001 P<0.005 P<0.05 NS NS P<0.005
LA treatment (LA) NS P<0.005 P<0.05 P<0.05 P<0.05 P<0.005 P<0.0001 P<0.005
PW-diet P<0.0001 P<0.0001 P<0.0001 P<0.0001 NS P<0.05 P<0.0001 P<0.0001
Interactions
MD × LA NS NS NS NS P<0.05 P<0.05 NS NS
LA × PW-diet P = 0.05 NS NS NS NS NS NS NS
MD × PW diet NS NS NS NS NS NS NS NS
MD × PW diet × LA NS NS NS NS NS NS NS NS
trend toward increased fasting plasma insulin levels in
MHF oﬀspring, but this diﬀerence did not reach statistical
signiﬁcance (P = 0.068). LA treatment had no eﬀect
on plasma insulin levels. A postweaning hf diet increas-
ed plasma insulin levels in all hf-fed groups (Table 2).
Fasting plasma glucose levels were similar between the
groups (Table 2). Blood BHB levels were not altered by
MHF diet or neonatal LA treatment but were signiﬁcantly
increased in all hf-fed oﬀspring compared to chow-fed
oﬀspring (Table 2).J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
Table 2: Fasting plasma leptin, insulin, glucose, and β-hydroxybutyrate (BHB) measurements and rectal temperature in CON and MHF
oﬀspring treated with either saline (S) or pegylated leptin antagonist (LA) as neonates and fed either a chow or hf diet after weaning. Data
are means ± SEM, n = 8–16 per group, no signiﬁcant statistical interactions.
Leptin (ng/mL) Insulin (ng/mL) Glucose (mmol/L) BHB (mmol/L) Rectal Temperature (◦C)
CON-S-chow 10.4 ± 0.8 2.9 ± 0.2 5.98 ± 0.26 1.07 ± 0.07 37.19 ± 0.18
CON-S-hf 34.1 ± 3.6 4.6 ± 0.4 6.06 ± 0.32 1.57 ± 0.14 37.14 ± 0.13
CON-LA-chow 11.2 ± 1.4 3.4 ± 0.6 6.07 ± 0.37 1.24 ± 0.14 36.63 ± 0.19
CON-LA-hf 24.4 ± 3.9 5.9 ± 0.7 5.91 ± 0.27 1.29 ± 0.16 37.08 ± 0.14
MHF-S-chow 20.9 ± 2.9 4.4 ± 0.9 5.96 ± 0.26 0.92 ± 0.08 37.32 ± 0.15
MHF-S-hf 36.1 ± 3.0 6.1 ± 0.7 5.82 ± 0.32 1.47 ± 0.10 37.63 ± 0.21
MHF-LA-chow 16.7 ± 2.8 4.0 ± 0.6 5.28 ± 0.34 1.05 ± 0.14 37.08 ± 0.19
MHF-LA-hf 31.8 ± 4.2 6.1 ± 0.9 5.24 ± 0.31 1.61 ± 0.14 37.28 ± 0.11
Main eﬀects
Maternal diet P<0.05 P<0.05 NS NS P<0.05
LA treatment NS NS NS NS P<0.05
PW-diet P<0.0001 P<0.0001 NS P<0.0001 NS
4. Discussion
These results have demonstrated for the ﬁrst time that
early-life manipulation of the leptin axis via neonatal leptin
antagonism can exert marked eﬀects on growth and body
composition, which are dependent upon prior maternal
nutrition status and postweaning diet. Investigators using
neonatal leptin treatment given to oﬀspring of normally
fed dams have shown increased adiposity and leptin and
insulin resistance in oﬀspring in later life [33–35]. The
present result shows that the reverse can hold true. Control
oﬀspring, given a leptin antagonist prior to being fed an
obesogenic hf diet postweaning, show an amelioration of
a diet-induced fat accumulation and reduced linear body
growth.Themarkedcontrastinadultphenotypeinoﬀspring
of normally nourished mothers, based on exposure to either
leptin or leptin antagonism during early-life development,
further serves to highlight how critical the maintenance of
leptin threshold levels is during this period of developmental
plasticity.
As we have shown previously [7], maternal high-fat
nutrition resulted in increased adiposity, leptin, and insulin
concentrations in oﬀspring compared to oﬀspring of control
mothers, independent of postweaning diet. There is a well-
characterized leptin surge in the ﬁrst two weeks of life
in the rodent [26] although the source of the leptin is
yet to be deﬁned with the surge occurring independently
of changes in neonatal body weight trajectory and milk
leptin intake [31]. We have previously shown that oﬀspring
of MHF mothers are hypoleptinemic at birth [7]. This
concurs with the increased sensitivity to body weight gain
in MHF neonates treated with the LA as compared to
CON oﬀspring. In other studies, hypoleptinemic oﬀspring
of mothers undernourished during pregnancy have either
a delayed [36] or premature leptin surge [27]. However,
there is little known about the leptin surge in models
of maternal obesity. Kirk et al. recently reported that rat
oﬀspring of mothers fed an obesogenic diet had normal
serum leptin levels at birth but displayed an ampliﬁed and
prolonged neonatal leptin surge, which was accompanied
by an elevation in leptin mRNA expression in abdominal
white adipose tissue [31]. However, it is unknown whether
the leptin surge in the MHF oﬀspring of the present study is
altered.
Although inborn leptin deﬁciency causes weight gain, it
is unclear whether induced leptin deﬁciency in adult wild-
type animals would be orexigenic. Leptin antagonists have
only recently become commercially available and provide an
invaluable tool for investigating central and peripheral
leptin deﬁciency and exploring the involvement of leptin in
metabolic processes. Previous reports using a nonpegylated
leptinantagonisthavebeenproblematic.Theextremelyshort
half-life of the antagonist necessitated administration of
supraphysiological doses to induce a clinical response and
was not suﬃcient to induce a true metabolic state of leptin
deﬁciency[32,37].Hormoneswithmolecularmassessimilar
to that of leptin are cleared primarily via the kidney with a
half life of only 8–30 minutes [38].
The eﬀect of early postnatal leptin blockade in normal
rat neonates has previously been reported in the study by
Attig et al. [39]. In this work, the authors studied the
long-term eﬀect of neonatal therapy with a non-pegylated
leptin antagonist (day 2 to day 13) in female Wistar rats
[39]. In contrast to the present study, they showed that
leptin antagonism induced a decrease in neonatal weight
gain, which has previously been commonly associated with
neonatalleptintreatment[30,40].Laterinlife,theleptindis-
ruption led to a higher sensitivity to diet-induced obesity, as
shown by a higher body weight gain when challenged with
a high-energy diet, associated with increased adiposity and
leptinemia. These animals also displayed a phenotype of
leptin resistance at 4 months, characterized by the inability
of treated animals to respond to leptin by failing to reduce
food intake and showing reduced birth weight. Overall, the
long-term eﬀect in the Attig study was paradoxically similar
to that reported for rats treated with leptin during neonatal8 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
life [30, 40]. Importantly, the molecule used as the leptin
antagonist was diﬀerent from the one used in our study.
Indeed in this work, the authors used the leptin mutein,
a molecule acting as an antagonist, with in vivo eﬀects pre-
viously validated only using intracerebroventricular, but not
subcutaneous, administration [41–44]. Furthermore, this
antagonist, obtained by alanine mutagenesis of amino acids
39 to 41-42, has an extremely short half-life and high doses
are required to produce a clinical response that is similar to a
true metabolic state of leptin resistance.
The present study utilised a recently developed rat-
speciﬁc pegylated LA whereby the attachment of polyethy-
lene glycol increased the overall molecule size to 70kDa. Pe-
gylation of the LA results in an approximate 30-fold increase
in in vivo half-life [32], thus true states of induced leptin
deﬁciency are possible at physiologic doses. To date, only
one prior study has examined the eﬀects of the pegylated
LA moiety, albeit in normal postweaning animals [37]w h e r e
it was shown that treatment with the pegylated LA to
postweaning mice results in a rapid and dramatic increase
in food intake and weight gain [32]. The blood brain barrier
(BBB) in the neonatal rat is relatively immature; pegylated
leptin antagonist has been shown to block circulating leptin
from crossing the BBB, an action that would attenuate the
anorexigenic eﬀect of leptin [32]. It is diﬃcult to extrapolate
the Elinav et al. study to the present study. The windows of
treatment are diﬀerent, BBB permeability is at diﬀerent
developmental stages (neonatal versus postweaning), and
oﬀspring responsiveness to leptin intervention is known to
elicit sexually dimorphic responses [29, 30]. In addition,
the work in the mouse examined the immediate pheno-
typic response to LA treatment, whereas the present study
examines a postnatal phenotype derived from an early-
life neonatal intervention. However, consistent with the re-
ports from mice, the present result demonstrated that LA
treatment induced a signiﬁcant increase in body weight over
the neonatal treatment period.
In the present study, neonatal leptin antagonism, despite
havingsigniﬁcanteﬀectsonpre-weaningweightsinoﬀspring
of MHF mothers, had no eﬀect on postnatal weight gain in
C O No rM H Fo ﬀspring fed the standard chow diet. There
was, however, a marked eﬀect of neonatal LA treatment in
reducing body weight gain in CON oﬀspring fed the hf diet
after weaning. Conversely, LA treatment to MHF oﬀspring
subsequently fed the hf diet had no signiﬁcant eﬀect on
body weight; independent of changes in body weight and
circulating plasma leptin concentrations. LA treatment sig-
niﬁcantly reduced fat deposit weight in CON but not MHF
oﬀspring. Interestingly, neonatal LA treatment did not alter
postweaning caloric intake, thus the observed changes in
body weight gain are independent of food intake and suggest
al a c ko fe ﬀect of LA administration on the arcuate nucleus
and related feeding circuitry, as has been reported with
neonatal leptin treatment in the ob/ob mouse [21].
Nose-anus lengths were increased in MHF oﬀspring but
not CON oﬀspring, which may suggest that altered eﬀects
on the growth-hormone- (GH-) insulin-like growth factor
(IGF) axis are mediated by neonatal LA exposure. The
observed change in tail length in CON and MHF LA-
treatedoﬀspring was unexpected but may have resulted from
altered thermoregulatory set-point processes as reﬂected in
the signiﬁcant diﬀerences in basal body temperature. In
the rat, a signiﬁcant portion of total body heat loss occurs
through sympathetically mediated changes in tail blood ﬂow
[45]. However, since rectal temperature was decreased in LA-
treated CON and MHF oﬀspring, it is diﬃcult to explain
the disparate changes in tail length to thermoregulatory
processes and, as with nose-anus length, may reﬂect LA-
induced alterations in the GH-IGF axis in MHF oﬀspring as
compared to controls or development of a thrifty metabolic
phenotypeasregardsthermogenesisandenergyexpenditure.
Future independent studies looking at brown fat thermo-
genesis and uncoupling proteins may further explain this
observation.
The eﬀect of LA on bone formation has not previously
beendescribed.Bonemorphologywassigniﬁcantlyalteredin
adult oﬀspring following neonatal LA treatment with overall
signiﬁcantreductionsinBMCandBMD.Itiswellestablished
that leptin treatment can result in enhanced bone formation
and promotion of pro-osteogenic factors in bone marrow
[46, 47], and the current data suggests that the reverse holds
true for leptin antagonism and further work investigating
speciﬁc bone markers is now warranted.
This is the ﬁrst study designed to examine the eﬃcacy of
neonatalleptinantagonismfollowingalteredmaternalnutri-
tion and its interaction with diﬀering levels of postweaning
nutrition, on oﬀspring phenotype development. Responsive-
ness to neonatal leptin antagonism is dependent upon both
maternal and postweaning nutrition, with minimal eﬃcacy
in chow-fed oﬀspring of either CON or MHF mothers.
More studies are now required to further understand the
mechanistic underpinnings of the present observations,
including characterization of the eﬀects of leptin antagonism
on the timing and magnitude of the leptin surge in oﬀspring
of mothers with diﬀerent dietary backgrounds. However, it is
important to recognise that leptin-mediated development of
feeding circuits occurs postnatally in the rodent and occurs
in utero in primates, including humans, and thus timing
of intervention strategies may be diﬀerent. Nonetheless,
taken together, the data on both neonatal leptin treatment
and leptin antagonism in the setting of both normal and
nutritionally challenged pregnancies serves to highlight the
important role of leptin regulation during critical early-life
windows of development on lasting growth and metabolic
function in oﬀspring.
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